• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pulmonary Fibrosis

Latest News

AJMC letter to the editor
Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

February 6th 2026

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.

A Lancet Respiratory Medicine study links telomere shortening and polygenic risk to distinct genetic endotypes in IPF. | Image Credit: lucadp-Adobestockjpeg
Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis

February 3rd 2026

In this Q&A, Na’am Avitzur, MD, discusses how pulmonary fibrosis impacts sexual health and why addressing quality of life matters.
Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD

February 2nd 2026

ACE inhibitors show promise in lowering mortality for IPF, suggesting new therapeutic potential for an existing medication. | Image credit: Елена Бутусова-stockk.adobe.com
ACE Inhibitors Linked to Reduced Mortality in Patients With Idiopathic Pulmonary Fibrosis

January 26th 2026

Patients with pulmonary fibrosis face physical and emotional challenges in sexual activity, underscoring the importance of comprehensive care beyond lung function. | Image Credit: @Vitalii Vodolazskyi-Adobestock.jpeg
Navigating Sexual Dysfunction in Patients With Pulmonary Fibrosis

January 22nd 2026

<12345
© 2026 MJH Life Sciences
AJMC®
All rights reserved.